Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes

Diabetic Medicine

Volumn 29, Issue 8, 2012, Pages 972-979

  Schofield, C J ^a   Sutherland, C ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

cell; Insulin resistance; Insulin secretion; Pathogenesis (Type2 diabetes)

Indexed keywords

INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; SULFONYLUREA;

CELL FUNCTION; CONTINUOUS INFUSION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LIPOLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS;

EID: 84864025055     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03655.x     Document Type: Review

References (74)

1. Rizza RA, Mandarino LJ, Genest J, Baker BA, Gerich JE. Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 1985; 28: 70-75.
2. Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type2 diabetes. Diabetes 2002; 51: S109-S116.
3. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93: 2438-2446.
4. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-32353.
5. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377.
6. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-3025.
7. Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ et al. Serine phosphorylation of insulin receptor substrate1 by inhibitor kappa B kinase complex. J Biol Chem 2002; 277: 48115-48121.
8. Wu J, Yang LJ, Zou DJ. Rosiglitazone attenuates tumor necrosis factor-alpha-induced protein tyrosine phosphatase-1B production in HepG2 cells. J Endocrinol Invest 2012; 35: 28-34.
9. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008; 14: 741-751.
10. Grapengiesser E, Gylfe E, Hellman B. Three types of cytoplasmic Ca2+ oscillations in stimulated pancreatic beta-cells. Arch Biochem Biophys 1989; 268: 404-407.
11. Gylfe E, Grapengiesser E, Hellman B. Propagation of cytoplasmic Ca2+ oscillations in clusters of pancreatic beta-cells exposed to glucose. Cell Calcium 1991; 12: 229-240.
12. Ainscow EK, Rutter GA. Glucose-stimulated oscillations in free cytosolic ATP concentration imaged in single islet beta-cells: evidence for a Ca2+-dependent mechanism. Diabetes 2002; 51: S162-S170.
13. Grapengiesser E, Gylfe E, Hellman B. Glucose-induced oscillations of cytoplasmic Ca2+ in the pancreatic beta-cell. Biochem Biophys Res Commun 1988; 151: 1299-1304.
14. Hellman B. Pulsatility of insulin release-a clinically important phenomenon. Ups J Med Sci 2009; 114: 193-205.
15. Ravier MA, Sehlin J, Henquin JC. Disorganization of cytoplasmic Ca(2+) oscillations and pulsatile insulin secretion in islets from ob/ob mice. Diabetologia 2002; 45: 1154-1163.
16. Ahren B. Autonomic regulation of islet hormone secretion-implications for health and disease. Diabetologia 2000; 43: 393-410.
17. Hellman B, Salehi A, Gylfe E, Dansk H, Grapengiesser E. Glucose generates coincident insulin and somatostatin pulses and antisynchronous glucagon pulses from human pancreatic islets. Endocrinology 2009; 150: 5334-5340.
18. Menge BA, Gruber L, Jorgensen SM, Deacon CF, Schmidt WE, Veldhuis JD et al. Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type2 diabetes. Diabetes 2011; 60: 2160-2168.
19. Song SH, McIntyre SS, Shah H, Veldhuis JD, Hayes PC, Butler PC. Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J Clin Endocrinol Metab 2000; 85: 4491-4499.
20. Porksen N, Munn S, Steers J, Veldhuis JD, Butler PC. Effects of glucose ingestion versus infusion on pulsatile insulin secretion. The incretin effect is achieved by amplification of insulin secretory burst mass. Diabetes 1996; 45: 1317-1323.
21. Porksen N, Munn S, Steers J, Vore S, Veldhuis J, Butler P. Pulsatile insulin secretion accounts for 70% of total insulin secretion during fasting. Am J Physiol 1995; 269: E478-E488.
22. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type2 diabetes. Diabetes 2003; 52: 102-110.
23. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ et al. Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989; 1: 293-295.
24. Hunter SJ, Atkinson AB, Ennis CN, Sheridan B, Bell PM. Association between insulin secretory pulse frequency and peripheral insulin action in NIDDM and normal subjects. Diabetes 1996; 45: 683-686.
25. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005; 90: 493-500.
26. Ferrannini E. The stunned beta-cell: a brief history. Cell Metab 2010; 11: 349-352.
27. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes 2005; 54: 1649-1656.
28. Laedtke T, Kjems L, Porksen N, Schmitz O, Veldhuis J, Kao PC et al. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type2 diabetes. Am J Physiol Endocrinol Metab 2000; 279: E520-E528.
29. Matveyenko AV, Veldhuis JD, Butler PC. Adaptations in pulsatile insulin secretion, hepatic insulin clearance, and beta-cell mass to age-related insulin resistance in rats. Am J Physiol Endocrinol Metab 2008; 295: E832-E841.
30. Leibiger IB, Leibiger B, Berggren PO. Insulin feedback action on pancreatic beta-cell function. FEBS Lett 2002; 532: 1-6.
31. Kulkarni RN, Holzenberger M, Shih DQ, Ozcan U, Stoffel M, Magnuson MA et al. Beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat Genet 2002; 31: 111-115.
32. Otani K, Kulkarni RN, Baldwin AC, Krutzfeldt J, Ueki K, Stoffel M et al. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in βIRKO mice. Am J Physiol Endocrinol Metab 2004; 286: E41-E49.
33. Bouche C, Lopez X, Fleischman A, Cypess AM, O'Shea S, Stefanovski D et al. Insulin enhances glucose-stimulated insulin secretion in healthy humans. Proc Natl Acad Sci U S A 2010; 107: 4770-4775.
34. Halperin F, Lopez X, Manning R, Kahn CR, Kulkarni RN, Goldfine AB. Insulin augmentation of glucose-stimulated insulin secretion is impaired in insulin-resistant humans. Diabetes 2012; 61: 301-309.
35. Holness MJ, Sugden MC. Damaging loss of self-control by stressed beta-cells. Diabetes 2012; 61: 267-269.
36. Goodner CJ, Sweet IR, Harrison HC Jr. Rapid reduction and return of surface insulin receptors after exposure to brief pulses of insulin in perifused rat hepatocytes. Diabetes 1988; 37: 1316-1323.
37. Marshall S, Olefsky JM. Effects of insulin incubation on insulin binding, glucose transport, and insulin degradation by isolated rat adipocytes. Evidence for hormone-induced desensitization at the receptor and postreceptor level. J Clin Invest 1980; 66: 763-772.
38. McGuinness OP, Friedman A, Cherrington AD. Intraportal hyperinsulinemia decreases insulin-stimulated glucose uptake in the dog. Metabolism 1990; 39: 127-132.
39. Marban SL, Roth J. Transgenic hyperinsulinemia: a mouse model of insulin resistance and glucose intolerance without obesity. In: Shafrir E, ed. Lessons from Animal Diabetes VI. 6th edn. Boston: Birkhauser, 1996: 201-224.
40. Stapelfeldt W, Bender H, Schusdziarra V, Pfeiffer EF. Effect of continuous and oscillatory portal vein insulin infusion upon glucose-induced insulin release in rats. Res Exp Med (Berl) 1984; 184: 67-71.
41. Bratusch-Marrain PR, Komjati M, Waldhausl WK. Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in typeI diabetic humans. Diabetes 1986; 35: 922-926.
42. Komjati M, Bratusch-Marrain P, Waldhausl W. Superior efficacy of pulsatile versus continuous hormone exposure on hepatic glucose production in vitro. Endocrinology 1986; 118: 312-319.
43. Berman N, Genter P, Chou HF, Cortez C, Bowsher R, Ipp E. Erratic oscillatory characteristics of plasma insulin concentrations in patients with insulinoma: mechanism for unpredictable hypoglycemia. J Clin Endocrinol Metab 1997; 82: 2899-2903.
44. Skrha J, Sindelka G, Haas T, Hilgertova J, Justova V. Comparison of insulin sensitivity in patients with insulinoma and obese Type2 diabetes mellitus. Horm Metab Res 1996; 28: 595-598.
45. Stadler M, Pacini G, Petrie J, Luger A, Anderwald C. Beta-cell (dys)function in non-diabetic offspring of diabetic patients. Diabetologia 2009; 52: 2435-2444.
46. O'Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 1988; 318: 1225-1230.
47. Petrie JR, Pearson ER, Sutherland C. Implications of genome-wide association studies for the understanding of type2 diabetes pathophysiology. Biochem Pharmacol 2011; 81: 471-477.
48. O'Rahilly S. Insights into obesity and insulin resistance from the study of extreme human phenotypes. Eur J Endocrinol 2002; 147: 435-441.
49. Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple RK, Dash S et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med 2009; 1: 280-287.
50. Dash S, Sano H, Rochford JJ, Semple RK, Yeo G, Hyden CS et al. A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia. Proc Natl Acad Sci USA 2009; 106: 9350-9355.
51. George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 2004; 304: 1325-1328.
52. Caro JF, Sinha MK, Raju SM, Ittoop O, Pories WJ, Flickinger EG et al. Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest 1987; 79: 1330-1337.
53. Gavin JR 3rd, Roth J, Neville DM Jr, de Meyts P, Buell DN. Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. Proc Natl Acad Sci U S A 1974; 71: 84-88.
54. DeMeyts P, Bainco AR, Roth J. Site-site interactions among insulin receptors. Characterization of the negative cooperativity. J Biol Chem 1976; 251: 1877-1888.
55. Seino S, Bell GI. Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun 1989; 159: 312-316.
56. Zick Y, Grunberger G, Podskalny JM, Moncada V, Taylor SI, Gorden P et al. Insulin stimulates phosphorylation of serine residues in soluble insulin receptors. Biochem Biophys Res Commun 1983; 116: 1129-1135.
57. Kusari J, Kenner KA, Suh KI, Hill DE, Henry RR. Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance. J Clin Invest 1994; 93: 1156-1162.
58. Krebs DL, Hilton DJ. A new role for SOCS in insulin action. Suppressor of cytokine signaling. Sci STKE 2003; 2003: PE6.
59. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002; 277: 1531-1537.
60. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000; 275: 9047-9054.
61. Lee YH, Giraud J, Davis RJ, White MF. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 2003; 278: 2896-2902.
62. Carlson CJ, White MF, Rondinone CM. Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation. Biochem Biophys Res Commun 2004; 316: 533-539.
63. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004; 166: 213-223.
64. Eldar-Finkelman H, Krebs EG. Phosphorylation of insulin receptor substrate1 by glycogen synthase kinase3 impairs insulin action. Proc Natl Acad Sci USA 1997; 94: 9660-9664.
65. De Fea K, Roth RA. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem 1997; 272: 31400-31406.
66. Porksen NK, Munn SR, Steers JL, Schmitz O, Veldhuis JD, Butler PC. Mechanisms of sulfonylurea's stimulation of insulin secretion in vivo: selective amplification of insulin secretory burst mass. Diabetes 1996; 45: 1792-1797.
67. Mirbolooki MR, Taylor GE, Knutzen VK, Scharp DW, Willcourt R, Lakey JR. Pulsatile intravenous insulin therapy: the best practice to reverse diabetes complications? Med Hypotheses 2009; 73: 363-369.
68. McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PW, Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004; 27: 538-546.
69. Liese AD, Schulz M, Fang F, Wolever TM, D'Agostino RB Jr, Sparks KC et al. Dietary glycemic index and glycemic load, carbohydrate and fiber intake, and measures of insulin sensitivity, secretion, and adiposity in the Insulin Resistance Atherosclerosis Study. Diabetes Care 2005; 28: 2832-2838.
70. Solomon TP, Haus JM, Kelly KR, Cook MD, Filion J, Rocco M et al. A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans. Am J Clin Nutr 2010; 92: 1359-1368.
71. McAuley KA, Hopkins CM, Smith KJ, McLay RT, Williams SM, Taylor RW et al. Comparison of high-fat and high-protein diets with a high-carbohydrate diet in insulin-resistant obese women. Diabetologia 2005; 48: 8-16.
72. Ferreira AV, Mario EG, Porto LC, Andrade SP, Botion LM. High-carbohydrate diet selectively induces tumor necrosis factor-alpha production in mice liver. Inflammation 2011; 34: 139-145.
73. Patane G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2000; 49: 735-740.
74. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004; 286: E560-E567.